CCL

Összesen 5 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM103789
035-os BibID:(WOS)000859802100001 (Scopus)85139865478
Első szerző:Charles-Schoeman, Christina
Cím:Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease : a post hoc analysis from ORAL Surveillance / Christina Charles-Schoeman, Maya H. Buch, Maxime Dougados, Deepak L. Bhatt, Jon T. Giles, Steven R. Ytterberg, Gary G. Koch, Ivana Vranic, Joseph Wu, Cunshan Wang, Kenneth Kwok, Sujatha Menon, Jose L. Rivas, Arne Yndestad, Carol A. Connell, Zoltan Szekanecz
Dátum:2022
ISSN:0003-4967
Megjegyzések:Objectives Evaluate risk of major adverse cardiovascular events (MACE) with tofacitinib versus tumour necrosis factor inhibitors (TNFi) in patients with rheumatoid arthritis (RA) with or without a history of atherosclerotic cardiovascular disease (ASCVD) in ORAL Surveillance. Methods Patients with RA aged >= 50 years with >= 1 additional CV risk factor received tofacitinib 5 mg or 10 mg two times per day or TNFi. Hazard rations (HRs) were evaluated for the overall population and by history of ASCVD (exploratory analysis). Results Risk of MACE, myocardial infarction and sudden cardiac death were increased with tofacitinib versus TNFi in ORAL Surveillance. In patients with history of ASCVD (14.7%; 640/4362), MACE incidence was higher with tofacitinib 5 mg two times per day (8.3%; 17/204) and 10 mg two times per day (7.7%; 17/222) versus TNFi (4.2%; 9/214). HR (combined tofacitinib doses vs TNFi) was 1.98 (95% confidence interval (CI) 0.95 to 4.14; interaction p values: 0.196 (for HR)/0.059 (for incidence rate difference)). In patients without history of ASCVD, MACE HRs for tofacitinib 5 mg two times per day (2.4%; 30/1251) and 10 mg two times per day (2.8%; 34/1234) versus TNFi (2.3%; 28/1237) were, respectively, 1.03 (0.62 to 1.73) and 1.25 (0.76 to 2.07). Conclusions This post hoc analysis observed higher MACE risk with tofacitinib versus TNFi in patients with RA and history of ASCVD. Among patients without history of ASCVD, all with prevalent CV risk factors, MACE risk did not appear different with tofacitinib 5 mg two times per day versus TNFi. Due to the exploratory nature of this analysis and low statistical power, we cannot exclude differential MACE risk for tofacitinib 5 mg two times per day versus TNFi among patients without history of ASCVD, but any absolute risk excess is likely low.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Antirheumatic Agents
Arthritis
Rheumatoid
Cardiovascular Diseases
Therapeutics
Megjelenés:Annals Of The Rheumatic Diseases. - 82 : 1 (2022), p. 119-129. -
További szerzők:Buch, Maya H. Dougados, Maxime Bhatt, Deepak L. Giles, Jon T. Ytterberg, Steven R. Koch, Gary G. Vranic, Ivana Wu, Joseph Wang, Cunshan Kwok, Kenneth Menon, Sujatha Rivas, Jose L. Yndestad, Arne Connell, Carol A. Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM108307
035-os BibID:(Scopus)85148667393 (WoS)000926215100001
Első szerző:Dougados, Maxime
Cím:Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme / Maxime Dougados, Christina Charles-Schoeman, Zoltán Szekanecz, Jon T. Giles, Steven R. Ytterberg, Deepak L. Bhatt, Gary G. Koch, Ivana Vranic, Joseph Wu, Cunshan Wang, Kenneth Kwok, Sujatha Menon, Carol A. Connell, Arne Yndestad, Jose L. Rivas, Maya H. Buch
Dátum:2023
ISSN:0003-4967
Tárgyszavak:Orvostudományok Klinikai orvostudományok levél
folyóiratcikk
Megjelenés:Annals Of The Rheumatic Diseases. - 82 : 4 (2023), p. 575-577. -
További szerzők:Charles-Schoeman, Christina Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Giles, Jon T. Ytterberg, Steven R. Bhatt, Deepak L. Koch, Gary G. Vranic, Ivana Wu, Joseph Wang, Cunshan Kwok, Kenneth Menon, Sujatha Connell, Carol A. Yndestad, Arne Rivas, Jose L. Buch, Maya H.
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM096109
035-os BibID:(WOS)000723328800001 (Scopus)85122302204
Első szerző:Nagy György
Cím:EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis / Nagy György, Roodenrijs Nadia M. T., Welsing Paco M. J., Kedves Melinda, Hamar Attila, van der Goes Marlies C., Kent Alison, Bakkers Margot, Pchelnikova Polina, Blaas Etienne, Senolt Ladislav, Szekanecz Zoltan, Choy Ernest H., Dougados Maxime, Jacobs Johannes W. G., Geenen Rinie, Bijlsma Johannes W. J., Zink Angela, Aletaha Daniel, Schoneveld Leonard, van Riel Piet, Dumas Sophie, Prior Yeliz, Nikiphorou Elena, Ferraccioli Gianfranco, Schett Georg, Hyrich Kimme L., Mueller-Ladner Ulf, Buch Maya H., McInnes Iain B., van der Heijde Désirée, van Laar Jacob M.
Dátum:2022
ISSN:0003-4967
Megjegyzések:Objective To develop evidence-based European Alliance of Associations for Rheumatology (EULAR) points to consider (PtCs) for the management of difficultto-treat rheumatoid arthritis (D2T RA). Methods An EULAR Task Force was established comprising 34 individuals: 26 rheumatologists, patient partners and rheumatology experienced health professionals. Two systematic literature reviews addressed clinical questions around diagnostic challenges, and pharmacological and nonpharmacological therapeutic strategies in D2T RA. PtCs were formulated based on the identified evidence and expert opinion. Strength of recommendations (SoR, scale A?D: A typically consistent level 1 studies and D level 5 evidence or inconsistent studies) and level of agreement (LoA, scale 0?10: 0 completely disagree and 10 completely agree) of the PtCs were determined by the Task Force members. Results Two overarching principles and 11 PtCs were defined concerning diagnostic confirmation of RA, evaluation of inflammatory disease activity, pharmacological and non-pharmacological interventions, treatment adherence, functional disability, pain, fatigue, goal setting and self-efficacy and the impact of comorbidities. The SoR varied from level C to level D. The mean LoA with the overarching principles and PtCs was generally high (8.4?9.6). Conclusions These PtCs for D2T RA can serve as a clinical roadmap to support healthcare professionals and patients to deliver holistic management and more personalised pharmacological and non-pharmacological therapeutic strategies. High-quality evidence was scarce. A research agenda was created to guide future research.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
arthritis
fibromyalgia
inflammation
rheumatoid
ultrasonography
Megjelenés:Annals Of The Rheumatic Diseases. - 81 : 1 (2022), p. 20-33. -
További szerzők:Roodenrijs, Nadia M. T. Welsing, Paco M. J. Kedves Melinda Hamar Attila Béla (1990-) (általános orvos) van der Goes, Marlies C. Kent, Alison Bakkers, Margôt Pchelnikova, Polina Blaas, Etienne Senolt, Ladislav Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Choy, Ernest Dougados, Maxime Jacobs, Johannes W. G. Geenen, Rinie Bijlsma, Johannes W. Zink, Angela Aletaha, Daniel Schoneveld, Leonard van Riel, Piet Dumas, Sophie Prior, Yeliz Nikiphorou, Elena (reumatológus) Ferraccioli, Gianfranco Schett, Georg Hyrich, Kimme L. Mueller-Ladner, Ulf Buch, Maya H. McInnes, Iain B. van der Heijde, Désirée van Laar, Jacob M.
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

4.

001-es BibID:BIBFORM088182
035-os BibID:(WOS)000607296800019 (Scopus)85098069546
Első szerző:Nagy György
Cím:EULAR definition of difficult-to-treat rheumatoid arthritis / György Nagy, Nadia M. T. Roodenrijs, Paco M. J. Welsing, Melinda Kedves, Attila Hamar, Marlies C. van der Goes, Alison Kent, Margot Bakkers, Etienne Blaas, Ladislav Senolt, Zoltan Szekanecz, Ernest Choy, Maxime Dougados, Johannes W. G. Jacobs, Rinie Geenen, Hans W. J. Bijlsma, Angela Zink, Daniel Aletaha, Leonard Schoneveld, Piet van Riel, Loriane Gutermann, Yeliz Prior, Elena Nikiphorou, Gianfranco Ferraccioli, Georg Schett, Kimme L. Hyrich, Ulf Mueller-Ladner, Maya H. Buch, Iain B. McInnes, Désirée van der Heijde, Jacob M. van Laar
Dátum:2021
ISSN:0003-4967
Megjegyzések:Background Despite treatment according to the current management recommendations, a significant proportion of patients with rheumatoid arthritis (RA) remain symptomatic. These patients can be considered to have 'difficult-to-treat RA'. However, uniform terminology and an appropriate definition are lacking. Objective The Task Force in charge of the "Development of EULAR recommendations for the comprehensive management of difficult-to-treat rheumatoid arthritis" aims to create recommendations for this underserved patient group. Herein, we present the definition of difficult-to-treat RA, as the first step. Methods The Steering Committee drafted a definition with suggested terminology based on an international survey among rheumatologists. This was discussed and amended by the Task Force, including rheumatologists, nurses, health professionals and patients, at a face-to-face meeting until sufficient agreement was reached (assessed through voting). Results The following three criteria were agreed by all Task Force members as mandatory elements of the definition of difficult-to-treat RA: (1) Treatment according to European League Against Rheumatism (EULAR) recommendation and failure of ?2 biological disease-modifying antirheumatic drugs (DMARDs)/targeted synthetic DMARDs (with different mechanisms of action) after failing conventional synthetic DMARD therapy (unless contraindicated); (2) presence of at least one of the following: at least moderate disease activity; signs and/or symptoms suggestive of active disease; inability to taper glucocorticoid treatment; rapid radiographic progression; RA symptoms that are causing a reduction in quality of life; and (3) the management of signs and/or symptoms is perceived as problematic by the rheumatologist and/or the patient. Conclusions The proposed EULAR definition for difficult-to-treat RA can be used in clinical practice, clinical trials and can form a basis for future research.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Annals Of The Rheumatic Diseases. - 80 : 1 (2021), p. 31-35. -
További szerzők:Roodenrijs, Nadia M. T. Welsing, Paco M. J. Kedves Melinda Hamar Attila Béla (1990-) (általános orvos) Goes, Marlies C. van der Kent, Alison Bakkers, Margôt Blaas, Etienne Senolt, Ladislav Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Choy, Ernest Dougados, Maxime Jacobs, Johannes W. G. Geenen, Rinie Bijlsma, Johannes W. Zink, Angela Aletaha, Daniel Schoneveld, Leonard Riel, Piet van Gutermann, Loriane Prior, Yeliz Nikiphorou, Elena (reumatológus) Ferraccioli, Gianfranco Schett, Georg Hyrich, Kimme L. Mueller-Ladner, Ulf Buch, Maya H. McInnes, Iain B. Heijde, Désirée van der Laar, Jacob M. van
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

5.

001-es BibID:BIBFORM117872
035-os BibID:(WoS)001142644000003 (Scopus)85182237892
Első szerző:Szekanecz Zoltán (reumatológus, belgyógyász, immunológus)
Cím:Efficacy and safety of JAK inhibitors in rheumatoid arthritis : update for the practising clinician / Zoltán Szekanecz, Maya H. Buch, Christina Charles-Schoeman, James Galloway, George A. Karpouzas, Lars Erik Kristensen, Steven R. Ytterberg, Attila Hamar, Roy Fleischmann
Dátum:2024
ISSN:1759-4790 1759-4804
Megjegyzések:Janus kinase (JAK) inhibitors, including tofacitinib, baricitinib, upadacitinib and filgotinib, are increasingly used in the treatment of rheumatoid arthritis (RA). There has been debate about their safety, particularly following the issuance of guidance by regulatory agencies advising caution in their use in certain patients. The registrational clinical trials and registry data of JAK inhibitors did not identify a difference in the risk of major adverse cardiovascular events (MACEs), venous thromboembolism, malignancies or infections (other than herpes zoster) with a JAK inhibitor versus a biologic DMARD. In the ORAL Surveillance trial, which enrolled patients >50 years of age with ?1 cardiovascular risk factor, tofacitinib was statistically inferior to TNF inhibitors for the occurrence of MACEs and malignancy. Further post hoc analysis of the data revealed that an age of ?65 years, a high baseline cardiovascular risk, a history of smoking, sustained inflammation, disease activity and suboptimal treatment of cardiovascular comorbidities all increase the risk of these outcomes. The guidance issued by regulatory agencies should be carefully considered to ensure appropriate and safe treatment of patients with RA without undertreatment of patients who might benefit from JAK inhibitor, as well as biologic, treatment. As always, the risks associated with the use of these agents, treatment goals, costs and patient preferences should be discussed with the patient.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Nature Reviews Rheumatology. - 20 : 2 (2024), p. 101-115. -
További szerzők:Buch, Maya H. Charles-Schoeman, Christina Galloway, James Karpouzas, George A. Kristensen, Lars Erik Ytterberg, Steven R. Hamar Attila Béla (1990-) (általános orvos) Fleischmann, Roy
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1 
Corvina könyvtári katalógus v8.2.27 © 2023 Monguz kft. Minden jog fenntartva.